International expansion -- Initial clinical use of ReCell Go in select European markets established post-CE Mark approval, ...

At this time, I would like to welcome everyone to the Inspire Medical Systems, Inc. fourth quarter and full year 2025 conference call. Ezgi Yagci: Thank you, Delam, and thank you all for participating ...

Inspire Medical Systems, Inc. (NYSE:INSP) Q4 2025 Earnings Call Transcript February 11, 2026 Inspire Medical Systems, Inc.

Chief Executive Officer — Eric Schlorff Chief Commercial Officer — Tim Varacek Chief Medical Officer — Kevin Chung Controller — Brad Town Investor Relations — Jackie Cossmon Chief Medical Officer ...

The permanence of artificial intelligence in healthcare is increasingly promising—and one of the most transformative use cases today is AI-powered medical transcription. AI medical scribes can reduce ...

Revenue-- $564,000 in revenue for fiscal Q2 2025 (period ended June 30, 2025), down from $901,000 in fiscal Q2 2024, reflecting a reduction attributed to lower procedure volumes and a shift in ...

Over the last 15 years serving the medical transcription industry, transcription technology has made a major impact on health care services. And the data agrees. By 2030 the medical transcription ...

IceCure Medical Ltd misses on earnings expectations. Reported EPS is $-0.06 EPS, expectations were $-0.05. Operator: Good morning, and thank you for standing by. Currently, all of the participants are ...

AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2025 Earnings Call Transcript February 12, 2026 AVITA Medical, Inc. beats earnings expectations. Reported EPS is $-0.04171, expectations were $-0.4835. Operator: ...

At this time, I would like to welcome everyone to the Inspire Medical Systems Fourth Quarter and Full Year 2025 Conference Call. [Operator Instructions] I'll now hand the call over to your first ...